(Heat Biologics, Inc.)

	HTBX latest price $155.4000 (-11.55%) ($154.7000 - $173.6000) on Tue. Jan. 19, 2016.
	Trend Analysis and Forecast
Average Daily Percentage Swing	18.42% (three month average)
RSI	55
Latest Price	$155.4000(-11.55%)
Stocks Behave Similarly	Similar Stock List
Daily Trend	HTBX declines -2% a day on average for past five trading days.
Market Behavior	Normal for large cap. Broad based sell-off for small cap.
Correlated ETFs	Broad market will support HTBX advance at 0% a week (0% probability)   SKYY(9%)    ARKK(8%)    FXI(8%)    KWEB(8%)    MCHI(8%)
Factors Impacting HTBX price	HTBX will decline at least -9.21% in a week (0% probabilities).   VIXM(-7%)    VCSH(-6%)    UUP(-3%)    GDXJ(-3%)    SHY(-2%)
Relative Volatility	(options are extremely cheap)
Market Trend Strength	-9.21% (StdDev 18.42%)
Hourly BBV	0 ()
Intraday Trend	-10.5%

5 Day Moving Average	$167.72(-7.35%)
10 Day Moving Average	$196.68(-20.99%)
20 Day Moving Average	$0(INF%)
To recent high	-48.6%
To recent low	1.4%
Market Cap	$17.098b

Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.

getNextHourMoveProbability failed